Evidence map›Paper›PMID 32997406›Full record

ArticleClinical and translational medicine2020

Irisin attenuates myocardial ischemia/reperfusion-induced cardiac dysfunction by regulating ER-mitochondria interaction through a mitochondrial ubiquitin ligase-dependent mechanism.

Linhe Lu, Jipeng Ma, Jiayou Tang, Yang Liu, Qijun Zheng, Shasha Chen, Erhe Gao, Jun Ren, Lifang Yang, Jian Yang

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 79 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Irisin deficiency exacerbates cardiac dysfunction and enhances hemorrhage injury in hemorrhage/resuscitation.American journal of physiology. Regulatory, integrative and comparative physiology · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Linhe LuDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
Jipeng MaDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
Jiayou TangDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
Yang LiuDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
Qijun ZhengDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
Shasha ChenDepartment of Cardiovascular Surgery, Shenzhen People's Hospital, Second Clinical Medical College, Jinan University, Shenzhen, China.
Erhe GaoCenter for Translational Medicine, Lewis Katz School of Medicine at Temple University., Philadelphia, Pennsylvania, USA.
Jun RenCenter for Cardiovascular Research and Alternative Medicine, University of Wyoming, Laramie, Wyoming, USA.
Lifang YangDepartment of Anesthesiology, Xi'an Children's Hospital, Xi'an, China.
Jian YangDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.ORCID https://orcid.org/0000-0003-2059-1912
Xijing Hospital · CNJinan University · CNTemple University · USUniversity of Wyoming · USXi’an Children’s Hospital · CN

Funding

Distinguished Young scholar foundation of Shaanxi Province 2018JC-015National Natural Science Foundation of China 81600240National Natural Science Foundation of China 81600295National Natural Science Foundation of China 81774415National Natural Science Foundation of China 81870216Subject Boosting Project of Xijing Hospital XJZT18MJ14Subject Boosting Project of Xijing Hospital XJZT18MJ69Subject Boosting Project of Xijing Hospital XJZT18Z02
6 · The paper itself

Abstract

backgroundMyocardial ischemia/reperfusion (MI/R) injury imposes devastating cardiovascular sequelae in particular cardiac dysfunction as a result of restored blood flow. However, the mechanism behind MI/R injury remains elusive. Mitochondrial ubiquitin ligase (MITOL/MARCH5) is localized at the mitochondria-ER contact site and may be activated in response to a variety of pathophysiological processes, such as apoptosis, mitochondrial injury, ER stress, hypoxia, and reactive oxygen species (ROS) generation. Irisin as a cleaved product of fibronectin type III domain-containing protein 5 (FNDC5) displays cardioprotection in diverse cardiac diseases.

methodsThis study was designed to examine the role of irisin and MITOL in MI/R injury. Male C57BL/6J mice (8-10-week-old) were administered adenovirus MITOL shRNA through intracardiac injection followed by MI/R surgery through ligation and release the slipknot of cardiac left anterior descending coronary artery.

resultsOur results showed that irisin improved myocardial function in the face of MI/R injury as evidenced by reduced myocardial infarct size, apoptotic rate, serum lactate dehydrogenase (LDH), ROS generation, and malondialdehyde (MDA) levels as well as lessened ER stress injury. Moreover, our results indicated that protective role of irisin was mediated by upregulation of MITOL. Irisin also protected H9c2 cells against simulated I/R through negating ER stress, apoptosis, ROS and MDA levels, as well as facilitating superoxide dismutase (SOD) by way of elevated MITOL expression.

conclusionsTo this end, our data favored that irisin pretreatment protects against MI/R injury, ER stress, ROS production, and mitochondrial homeostasis through upregulation of MITOL. These findings depicted the therapeutic potential of irisin and MITOL in the management of MI/R injury in patients with ST-segment elevation.

Indexed as

apoptosisendoplasmic reticulum stressirisin (FNDC5)mitochondrial ubiquitin ligase (MITOL)myocardial ischemia/reperfusion (MI/R)reactive oxygen species (ROS)

Identifiers

PMID32997406
PMCPMC7507588
OpenAlexW3086275909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.